Results 231 to 240 of about 32,846 (250)

Effect of liraglutide on the dysglycemia, inflammation, and gut microbiota in prediabetic KKay mice. [PDF]

Front Pharmacol
Zhang Y, Yang X, Yang P, Sun H, Chen L, Zhang X, Liu S.   +6 more
europepmc   +1 more source

Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment. [PDF]

Curr Obes Rep
Tentolouris A, Koufakis T, Fousteris E.
europepmc   +1 more source

Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.

JAMA Intern Med
Zhu H, Yang B, Lu L, Li Y, Sui R, Liu K, Tan S, Wang L, Qiu J, Zhong J, Wei T, Bei Y, Huang J, Zhang S, Ji Y, Wu W, Li Y, Huang Y, Chen Y, Huang X, Zeng G, Zhang Y, Huang L, Li H, Wang X, Wang Y, Xu A, LAMP Investigators.   +27 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Liraglutide

Nature Reviews Drug Discovery, 2010
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Daniel J, Drucker, Argyris, Dritselis, Peter, Kirkpatrick   +2 more
openaire   +2 more sources

[Liraglutide].

Nihon rinsho. Japanese journal of clinical medicine, 2011
Liraglutide is the first once-daily human GLP-1 analogue developed for the treatment of type 2 diabetes mellitus(T2DM). The half-life of liraglutide is 13 h following subcutaneous injection, making it suitable for once-daily dosing. Clinical data indicates improved beta cell function with liraglutide treatment in patients with T2DM.
Tomono, Takahashi, Masato, Odawara
openaire   +3 more sources

Liraglutide

Reactions Weekly, 2023
  +8 more sources

Liraglutide

Reactions Weekly, 2015
  +8 more sources